| Holli Ann Burden, | |
|
251 North Bayou Street, Mobile, AL 36603-5827 | |
| (251) 690-8158 | |
| (251) 544-2188 |
| Full Name | Holli Ann Burden |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 16 Years |
| Location | 251 North Bayou Street, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013166826 | NPI | - | NPPES |
| 1063439065 | Other | AL | NPI GROUP PAYEE NUMBER |
| 630000013 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 1-093057 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franklin Primary Health Center, Inc. | 1658356308 | 39 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
Today's headlines include reports about the politics surrounding the health law, both in terms of the latest GOP push for repeal and the Obama administration's implementation efforts.
A new study published in the July 11 issue of the Journal of Neuroscience details the development of the first mouse model engineered to carry the most common mutation in Usher syndrome III causative gene (Clarin-1) in North America.
Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc., will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 3 days ago
| Entity Name | Franklin Primary Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679532303 PECOS PAC ID: 1658356308 Enrollment ID: O20040618000827 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
Today's headlines include reports about the politics surrounding the health law, both in terms of the latest GOP push for repeal and the Obama administration's implementation efforts.
A new study published in the July 11 issue of the Journal of Neuroscience details the development of the first mouse model engineered to carry the most common mutation in Usher syndrome III causative gene (Clarin-1) in North America.
Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc., will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 3 days ago
| Entity Name | Alabama Post-acute Medical Service 1 Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073052403 PECOS PAC ID: 7416229406 Enrollment ID: O20170825002379 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
Today's headlines include reports about the politics surrounding the health law, both in terms of the latest GOP push for repeal and the Obama administration's implementation efforts.
A new study published in the July 11 issue of the Journal of Neuroscience details the development of the first mouse model engineered to carry the most common mutation in Usher syndrome III causative gene (Clarin-1) in North America.
Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc., will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 3 days ago
| Entity Name | Nm Pacs 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366928749 PECOS PAC ID: 3375892060 Enrollment ID: O20191109000048 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
Today's headlines include reports about the politics surrounding the health law, both in terms of the latest GOP push for repeal and the Obama administration's implementation efforts.
A new study published in the July 11 issue of the Journal of Neuroscience details the development of the first mouse model engineered to carry the most common mutation in Usher syndrome III causative gene (Clarin-1) in North America.
Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc., will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Holli Ann Burden, 251 N Bayou St, Mobile, AL 36603-5827 Ph: (251) 690-8158 | Holli Ann Burden, 251 North Bayou Street, Mobile, AL 36603-5827 Ph: (251) 690-8158 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
Today's headlines include reports about the politics surrounding the health law, both in terms of the latest GOP push for repeal and the Obama administration's implementation efforts.
A new study published in the July 11 issue of the Journal of Neuroscience details the development of the first mouse model engineered to carry the most common mutation in Usher syndrome III causative gene (Clarin-1) in North America.
Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc., will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.
Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.
› Verified 3 days ago
Mrs. Jennifer Gallagher Williams, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1601 Center St, Ste 1s, Mobile, AL 36604 Phone: 251-410-5437 Fax: 251-434-3852 | |
Mrs. Kathleen R. Carlen-magnone, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 6801 Airport Blvd, Mobile, AL 36608 Phone: 251-639-5775 Fax: 251-631-3581 | |
Kayla Clemons, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 6144 Airport Blvd, Mobile, AL 36608 Phone: 251-476-5050 Fax: 251-450-2770 | |
Mackenzie Krebsbach Roberts, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2451 University Hospital Dr, Mobile, AL 36617 Phone: 251-471-7565 | |
Lauren Marie Mcminn, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1855 Spring Hill Ave, Mobile, AL 36607 Phone: 251-471-3544 Fax: 251-476-7456 | |
Katherine Kinsaul, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-435-2620 | |
Wesley Kyle Dees, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2451 University Hospital Dr, Mstn 101, Mobile, AL 36617 Phone: 251-445-8282 Fax: 251-445-8281 |